Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Efficient estimation of grouped survival models.

Li Z, Lin J, Sibley AB, Truong T, Chua KC, Jiang Y, McCarthy J, Kroetz DL, Allen A, Owzar K.

BMC Bioinformatics. 2019 May 28;20(1):269. doi: 10.1186/s12859-019-2899-x.

2.

Organic Anion Transporter Polypeptide 1B1 Polymorphism Modulates the Extent of Drug-Drug Interaction and Associated Biomarker Levels in Healthy Volunteers.

Yee SW, Giacomini MM, Shen H, Humphreys WG, Horng H, Brian W, Lai Y, Kroetz DL, Giacomini KM.

Clin Transl Sci. 2019 Apr 13. doi: 10.1111/cts.12625. [Epub ahead of print]

PMID:
30982223
3.

Apical Shear Stress Enhanced Organic Cation Transport in Human OCT2/MATE1-Transfected Madin-Darby Canine Kidney Cells Involves Ciliary Sensing.

Jayagopal A, Brakeman PR, Soler P, Ferrell N, Fissell W, Kroetz DL, Roy S.

J Pharmacol Exp Ther. 2019 Jun;369(3):523-530. doi: 10.1124/jpet.118.255026. Epub 2019 Mar 25.

PMID:
30910922
4.

A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance).

Rashkin SR, Chua KC, Ho C, Mulkey F, Jiang C, Mushiroda T, Kubo M, Friedman PN, Rugo HS, McLeod HL, Ratain MJ, Castillos F, Naughton M, Overmoyer B, Toppmeyer D, Witte JS, Owzar K, Kroetz DL.

Clin Pharmacol Ther. 2019 Mar;105(3):738-745. doi: 10.1002/cpt.1241. Epub 2018 Nov 1.

PMID:
30260474
5.

Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle.

Bartelink IH, Jones EF, Shahidi-Latham SK, Lee PRE, Zheng Y, Vicini P, van 't Veer L, Wolf D, Iagaru A, Kroetz DL, Prideaux B, Cilliers C, Thurber GM, Wimana Z, Gebhart G.

Clin Pharmacol Ther. 2018 Aug 14. doi: 10.1002/cpt.1211. [Epub ahead of print] Review.

PMID:
30107040
6.

CYP2B6 Genetic Polymorphisms, Depression, and Viral Suppression in Adults Living with HIV Initiating Efavirenz-Containing Antiretroviral Therapy Regimens in Uganda: Pooled Analysis of Two Prospective Studies.

Chang JL, Lee SA, Tsai AC, Musinguzi N, Muzoora C, Bwana B, Boum Y 2nd, Haberer JE, Hunt PW, Martin J, Bangsberg DR, Kroetz DL, Siedner MJ.

AIDS Res Hum Retroviruses. 2018 Nov;34(11):982-992. doi: 10.1089/AID.2018.0062. Epub 2018 Aug 15.

PMID:
29973058
7.

Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance).

Li M, Mulkey F, Jiang C, O'Neil BH, Schneider BP, Shen F, Friedman PN, Momozawa Y, Kubo M, Niedzwiecki D, Hochster HS, Lenz HJ, Atkins JN, Rugo HS, Halabi S, Kelly WK, McLeod HL, Innocenti F, Ratain MJ, Venook AP, Owzar K, Kroetz DL.

Clin Cancer Res. 2018 Oct 1;24(19):4734-4744. doi: 10.1158/1078-0432.CCR-17-1523. Epub 2018 Jun 5.

PMID:
29871907
8.

Rare Variants in the ABCG2 Promoter Modulate In Vivo Activity.

Eclov RJ, Kim MJ, Smith R, Ahituv N, Kroetz DL.

Drug Metab Dispos. 2018 May;46(5):636-642. doi: 10.1124/dmd.117.079541. Epub 2018 Feb 21.

9.

Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci.

Sucheston-Campbell LE, Clay-Gilmour AI, Barlow WE, Budd GT, Stram DO, Haiman CA, Sheng X, Yan L, Zirpoli G, Yao S, Jiang C, Owzar K, Hershman D, Albain KS, Hayes DF, Moore HC, Hobday TJ, Stewart JA, Rizvi A, Isaacs C, Salim M, Gralow JR, Hortobagyi GN, Livingston RB, Kroetz DL, Ambrosone CB.

Pharmacogenet Genomics. 2018 Feb;28(2):49-55. doi: 10.1097/FPC.0000000000000318.

10.

Dicloxacillin induces CYP2C19, CYP2C9 and CYP3A4 in vivo and in vitro.

Stage TB, Graff M, Wong S, Rasmussen LL, Nielsen F, Pottegård A, Brøsen K, Kroetz DL, Khojasteh SC, Damkier P.

Br J Clin Pharmacol. 2018 Mar;84(3):510-519. doi: 10.1111/bcp.13467. Epub 2018 Jan 10.

11.

ABCG2 regulatory single-nucleotide polymorphisms alter in vivo enhancer activity and expression.

Eclov RJ, Kim MJ, Chhibber A, Smith RP, Ahituv N, Kroetz DL.

Pharmacogenet Genomics. 2017 Dec;27(12):454-463. doi: 10.1097/FPC.0000000000000312.

12.

Bevacizumab-induced hypertension: Clinical presentation and molecular understanding.

Li M, Kroetz DL.

Pharmacol Ther. 2018 Feb;182:152-160. doi: 10.1016/j.pharmthera.2017.08.012. Epub 2017 Sep 4. Review.

13.

Clinical Pharmacokinetics of Paclitaxel Monotherapy: An Updated Literature Review.

Stage TB, Bergmann TK, Kroetz DL.

Clin Pharmacokinet. 2018 Jan;57(1):7-19. doi: 10.1007/s40262-017-0563-z. Review.

PMID:
28612269
14.

Genetic advances uncover mechanisms of chemotherapy-induced peripheral neuropathy.

Chua KC, Kroetz DL.

Clin Pharmacol Ther. 2017 Apr;101(4):450-452. doi: 10.1002/cpt.590. Epub 2017 Feb 22.

15.

In Vivo Hepatic Enhancer Elements in the Human ABCG2 Locus.

Eclov RJ, Kim MJ, Smith RP, Liang X, Ahituv N, Kroetz DL.

Drug Metab Dispos. 2017 Feb;45(2):208-215. doi: 10.1124/dmd.116.072033. Epub 2016 Nov 17.

16.

ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia.

Li M, Seiser EL, Baldwin RM, Ramirez J, Ratain MJ, Innocenti F, Kroetz DL.

Pharmacogenomics J. 2018 Jan;18(1):35-42. doi: 10.1038/tpj.2016.75. Epub 2016 Nov 15.

17.

Best Practices for Clinical and Translational Research and Implementation.

Kroetz DL.

Clin Transl Sci. 2016 Oct;9(5):231-232. doi: 10.1111/cts.12411. Epub 2016 Sep 12. No abstract available.

18.

Metabolomic and Genome-wide Association Studies Reveal Potential Endogenous Biomarkers for OATP1B1.

Yee SW, Giacomini MM, Hsueh CH, Weitz D, Liang X, Goswami S, Kinchen JM, Coelho A, Zur AA, Mertsch K, Brian W, Kroetz DL, Giacomini KM.

Clin Pharmacol Ther. 2016 Nov;100(5):524-536. doi: 10.1002/cpt.434. Epub 2016 Sep 20.

19.

Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy.

Hertz DL, Owzar K, Lessans S, Wing C, Jiang C, Kelly WK, Patel J, Halabi S, Furukawa Y, Wheeler HE, Sibley AB, Lassiter C, Weisman L, Watson D, Krens SD, Mulkey F, Renn CL, Small EJ, Febbo PG, Shterev I, Kroetz DL, Friedman PN, Mahoney JF, Carducci MA, Kelley MJ, Nakamura Y, Kubo M, Dorsey SG, Dolan ME, Morris MJ, Ratain MJ, McLeod HL.

Clin Cancer Res. 2016 Oct 1;22(19):4890-4900. Epub 2016 May 3.

20.

Host genetic predictors of the kynurenine pathway of tryptophan catabolism among treated HIV-infected Ugandans.

Lee SA, Mefford JA, Huang Y, Witte JS, Martin JN, Haas DW, Mclaren PJ, Mushiroda T, Kubo M, Byakwaga H, Hunt PW, Kroetz DL.

AIDS. 2016 Jul 17;30(11):1807-15. doi: 10.1097/QAD.0000000000001124.

21.

Transcriptomic variation of pharmacogenes in multiple human tissues and lymphoblastoid cell lines.

Chhibber A, French CE, Yee SW, Gamazon ER, Theusch E, Qin X, Webb A, Papp AC, Wang A, Simmons CQ, Konkashbaev A, Chaudhry AS, Mitchel K, Stryke D, Ferrin TE, Weiss ST, Kroetz DL, Sadee W, Nickerson DA, Krauss RM, George AL, Schuetz EG, Medina MW, Cox NJ, Scherer SE, Giacomini KM, Brenner SE.

Pharmacogenomics J. 2017 Mar;17(2):137-145. doi: 10.1038/tpj.2015.93. Epub 2016 Feb 9.

22.

Transforming Translation: Impact of Clinical and Translational Science.

Wagner JA, Kroetz DL.

Clin Transl Sci. 2016 Feb;9(1):3-5. doi: 10.1111/cts.12380. Epub 2016 Jan 15. No abstract available.

23.

Multidrug resistance-associated protein 4 is a determinant of arsenite resistance.

Yuan B, Yoshino Y, Fukushima H, Markova S, Takagi N, Toyoda H, Kroetz DL.

Oncol Rep. 2016 Jan;35(1):147-54. doi: 10.3892/or.2015.4343. Epub 2015 Oct 22.

PMID:
26497925
24.

Pharmacoethnicity in Paclitaxel-Induced Sensory Peripheral Neuropathy.

Komatsu M, Wheeler HE, Chung S, Low SK, Wing C, Delaney SM, Gorsic LK, Takahashi A, Kubo M, Kroetz DL, Zhang W, Nakamura Y, Dolan ME.

Clin Cancer Res. 2015 Oct 1;21(19):4337-46. doi: 10.1158/1078-0432.CCR-15-0133. Epub 2015 May 26.

25.

SOX11 identified by target gene evaluation of miRNAs differentially expressed in focal and non-focal brain tissue of therapy-resistant epilepsy patients.

Haenisch S, Zhao Y, Chhibber A, Kaiboriboon K, Do LV, Vogelgesang S, Barbaro NM, Alldredge BK, Lowenstein DH, Cascorbi I, Kroetz DL.

Neurobiol Dis. 2015 May;77:127-40. doi: 10.1016/j.nbd.2015.02.025. Epub 2015 Mar 10.

26.

PharmGKB summary: very important pharmacogene information for human leukocyte antigen B.

Barbarino JM, Kroetz DL, Klein TE, Altman RB.

Pharmacogenet Genomics. 2015 Apr;25(4):205-21. doi: 10.1097/FPC.0000000000000118. No abstract available.

27.

Genomic architecture of pharmacological efficacy and adverse events.

Chhibber A, Kroetz DL, Tantisira KG, McGeachie M, Cheng C, Plenge R, Stahl E, Sadee W, Ritchie MD, Pendergrass SA.

Pharmacogenomics. 2014 Dec;15(16):2025-48. doi: 10.2217/pgs.14.144. Review.

28.

PharmGKB summary: abacavir pathway.

Barbarino JM, Kroetz DL, Altman RB, Klein TE.

Pharmacogenet Genomics. 2014 May;24(5):276-82. doi: 10.1097/FPC.0000000000000040. No abstract available.

29.

Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update.

Martin MA, Hoffman JM, Freimuth RR, Klein TE, Dong BJ, Pirmohamed M, Hicks JK, Wilkinson MR, Haas DW, Kroetz DL; Clinical Pharmacogenetics Implementation Consortium.

Clin Pharmacol Ther. 2014 May;95(5):499-500. doi: 10.1038/clpt.2014.38. Epub 2014 Feb 21.

30.

Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance).

Chhibber A, Mefford J, Stahl EA, Pendergrass SA, Baldwin RM, Owzar K, Li M, Winer EP, Hudis CA, Zembutsu H, Kubo M, Nakamura Y, McLeod HL, Ratain MJ, Shulman LN, Ritchie MD, Plenge RM, Witte JS, Kroetz DL.

Pharmacogenomics J. 2014 Aug;14(4):336-42. doi: 10.1038/tpj.2014.2. Epub 2014 Feb 11.

31.

Response to "CYP2C9 polymorphism is not a major determinant of bosentan exposure in healthy volunteers".

Markova SM, Schwartz JB, Kroetz DL.

Clin Pharmacol Ther. 2014 Mar;95(3):252. doi: 10.1038/clpt.2013.239. Epub 2013 Dec 17. No abstract available.

PMID:
24346422
32.

Expression of six drug transporters in vaginal, cervical, and colorectal tissues: Implications for drug disposition in HIV prevention.

Nicol MR, Fedoriw Y, Mathews M, Prince HM, Patterson KB, Geller E, Mollan K, Mathews S, Kroetz DL, Kashuba AD.

J Clin Pharmacol. 2014 May;54(5):574-83. doi: 10.1002/jcph.248. Epub 2014 Jan 2.

33.

ABCC4 is regulated by microRNA-124a and microRNA-506.

Markova SM, Kroetz DL.

Biochem Pharmacol. 2014 Feb 1;87(3):515-22. doi: 10.1016/j.bcp.2013.10.017. Epub 2013 Oct 30.

34.

Epoxyeicosatrienoic acids prevent cisplatin-induced renal apoptosis through a p38 mitogen-activated protein kinase-regulated mitochondrial pathway.

Liu Y, Lu X, Nguyen S, Olson JL, Webb HK, Kroetz DL.

Mol Pharmacol. 2013 Dec;84(6):925-34. doi: 10.1124/mol.113.088302. Epub 2013 Oct 3.

35.

Measuring the overall genetic component of nevirapine pharmacokinetics and the role of selected polymorphisms: towards addressing the missing heritability in pharmacogenetic phenotypes?

Micheli JE, Chinn LW, Shugarts SB, Patel A, Martin JN, Bangsberg DR, Kroetz DL.

Pharmacogenet Genomics. 2013 Nov;23(11):591-6. doi: 10.1097/FPC.0b013e32836533a5.

36.

Association of CYP2C9*2 with bosentan-induced liver injury.

Markova SM, De Marco T, Bendjilali N, Kobashigawa EA, Mefford J, Sodhi J, Le H, Zhang C, Halladay J, Rettie AE, Khojasteh C, McGlothlin D, Wu AH, Hsueh WC, Witte JS, Schwartz JB, Kroetz DL.

Clin Pharmacol Ther. 2013 Dec;94(6):678-86. doi: 10.1038/clpt.2013.143. Epub 2013 Jul 17.

37.

OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis.

Tamraz B, Fukushima H, Wolfe AR, Kaspera R, Totah RA, Floyd JS, Ma B, Chu C, Marciante KD, Heckbert SR, Psaty BM, Kroetz DL, Kwok PY.

Pharmacogenet Genomics. 2013 Jul;23(7):355-64. doi: 10.1097/FPC.0b013e3283620c3b.

38.

Abacavir pharmacogenetics--from initial reports to standard of care.

Martin MA, Kroetz DL.

Pharmacotherapy. 2013 Jul;33(7):765-75. doi: 10.1002/phar.1278. Epub 2013 May 3. Review.

39.

Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy.

Wheeler HE, Gamazon ER, Wing C, Njiaju UO, Njoku C, Baldwin RM, Owzar K, Jiang C, Watson D, Shterev I, Kubo M, Zembutsu H, Winer EP, Hudis CA, Shulman LN, Nakamura Y, Ratain MJ, Kroetz DL; Cancer and Leukemia Group B, Cox NJ, Dolan ME.

Clin Cancer Res. 2013 Jan 15;19(2):491-9. doi: 10.1158/1078-0432.CCR-12-2618. Epub 2012 Nov 30.

40.

The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance).

Lewis LD, Miller AA, Owzar K, Bies RR, Markova S, Jiang C, Kroetz DL, Egorin MJ, McLeod HL, Ratain MJ; Alliance for Clinical Trials in Oncology.

Pharmacogenet Genomics. 2013 Jan;23(1):29-33. doi: 10.1097/FPC.0b013e32835b16d8.

41.

Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.

Nakamura Y, Ratain MJ, Cox NJ, McLeod HL, Kroetz DL, Flockhart DA.

J Natl Cancer Inst. 2012 Aug 22;104(16):1264; author reply 1266-8. doi: 10.1093/jnci/djs304. Epub 2012 Jul 31. No abstract available.

PMID:
22851270
42.

A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101.

Baldwin RM, Owzar K, Zembutsu H, Chhibber A, Kubo M, Jiang C, Watson D, Eclov RJ, Mefford J, McLeod HL, Friedman PN, Hudis CA, Winer EP, Jorgenson EM, Witte JS, Shulman LN, Nakamura Y, Ratain MJ, Kroetz DL.

Clin Cancer Res. 2012 Sep 15;18(18):5099-109. Epub 2012 Jul 27.

43.

Functional characterization of ABCC2 promoter polymorphisms and allele-specific expression.

Nguyen TD, Markova S, Liu W, Gow JM, Baldwin RM, Habashian M, Relling MV, Ratain MJ, Kroetz DL.

Pharmacogenomics J. 2013 Oct;13(5):396-402. doi: 10.1038/tpj.2012.20. Epub 2012 Jun 5.

44.

Attenuation of cisplatin-induced renal injury by inhibition of soluble epoxide hydrolase involves nuclear factor κB signaling.

Liu Y, Webb HK, Fukushima H, Micheli J, Markova S, Olson JL, Kroetz DL.

J Pharmacol Exp Ther. 2012 Jun;341(3):725-34. doi: 10.1124/jpet.111.191247. Epub 2012 Mar 13.

45.

Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.

Martin MA, Klein TE, Dong BJ, Pirmohamed M, Haas DW, Kroetz DL; Clinical Pharmacogenetics Implementation Consortium.

Clin Pharmacol Ther. 2012 Apr;91(4):734-8. doi: 10.1038/clpt.2011.355. Epub 2012 Feb 29. Review.

46.

Contribution of aquaporin 9 and multidrug resistance-associated protein 2 to differential sensitivity to arsenite between primary cultured chorion and amnion cells prepared from human fetal membranes.

Yoshino Y, Yuan B, Kaise T, Takeichi M, Tanaka S, Hirano T, Kroetz DL, Toyoda H.

Toxicol Appl Pharmacol. 2011 Dec 1;257(2):198-208. doi: 10.1016/j.taap.2011.09.006. Epub 2011 Sep 16.

47.

Cerivastatin, genetic variants, and the risk of rhabdomyolysis.

Marciante KD, Durda JP, Heckbert SR, Lumley T, Rice K, McKnight B, Totah RA, Tamraz B, Kroetz DL, Fukushima H, Kaspera R, Bis JC, Glazer NL, Li G, Austin TR, Taylor KD, Rotter JI, Jaquish CE, Kwok PY, Tracy RP, Psaty BM.

Pharmacogenet Genomics. 2011 May;21(5):280-8. doi: 10.1097/FPC.0b013e328343dd7d.

48.

Discovery of regulatory elements in human ATP-binding cassette transporters through expression quantitative trait mapping.

Matsson P, Yee SW, Markova S, Morrissey K, Jenkins G, Xuan J, Jorgenson E, Kroetz DL, Giacomini KM.

Pharmacogenomics J. 2012 Jun;12(3):214-26. doi: 10.1038/tpj.2011.8. Epub 2011 Mar 8.

49.

Functional characterization of liver enhancers that regulate drug-associated transporters.

Kim MJ, Skewes-Cox P, Fukushima H, Hesselson S, Yee SW, Ramsey LB, Nguyen L, Eshragh JL, Castro RA, Wen CC, Stryke D, Johns SJ, Ferrin TE, Kwok PY, Relling MV, Giacomini KM, Kroetz DL, Ahituv N.

Clin Pharmacol Ther. 2011 Apr;89(4):571-8. doi: 10.1038/clpt.2010.353. Epub 2011 Mar 2.

50.

Exploiting the complexity of the genome and transcriptome using pharmacogenomics towards personalized medicine.

Hoppe R, Brauch H, Kroetz DL, Esteller M.

Genome Biol. 2011;12(1):301. doi: 10.1186/gb-2011-12-1-301. Epub 2011 Jan 17.

Supplemental Content

Loading ...
Support Center